Human antibodies to rift valley fever virus

A method of treating a subject infected with Rift Valley Fever Virus or reducing the likelihood of infection of a subject at risk of contracting Rift Valley Fever Virus, comprising delivering to said subject an antibody or antibody fragment comprising (i) heavy chain CDR1-3 comprising SEQ ID NO:

• 346, SEQ ID NO:
• 347 and SEQ ID NO:
• 348, respectively, and light chain CDR1-3 comprising SEQ ID NO:
• 592, SEQ ID NO:
• 593 and SEQ ID NO:
• 594, respectively;
• (ii) heavy chain CDR1-3 comprising SEQ ID NO:
• 424, SEQ ID NO:
• 425 and SEQ ID NO:
• 426, respectively, and light chain CDR1-3 comprising SEQ ID NO:
• 670, SEQ ID NO:
• 671 and SEQ ID NO:
• 672, respectively;
• or (iii) heavy chain CDR1-3 comprising SEQ ID NO:
• 532, SEQ ID NO:
• 533 and SEQ ID NO:
• 534, respectively, and light chain CDR1-3 comprising SEQ ID NO:
• 775, SEQ ID NO:
• 776 and SEQ ID NO:
• 777, respectively.